{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:44:53Z","timestamp":1791999893037,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100360","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:29:20Z","timestamp":1783380560000},"page":"100360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A 3-step static mechanistic modeling approach to predicting transporter- and enzyme-mediated interaction signals of direct oral anticoagulants"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6494-2597","authenticated-orcid":false,"given":"Mostafa","family":"ben Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8265","authenticated-orcid":false,"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-5692","authenticated-orcid":false,"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.dmd.2026.100360_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.dmd.2026.100360_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11239-013-0929-5","article-title":"Pharmacology of the new target-specific oral anticoagulants","volume":"36","author":"Cabral","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100360_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Sikorska","year":"2017","journal-title":"Eur Cardiol Rev"},{"issue":"5","key":"10.1016\/j.dmd.2026.100360_bib8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100360_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40256-019-00348-2","article-title":"The effects of clarithromycin on the pharmacokinetics of apixaban in healthy volunteers: a single-sequence crossover study","volume":"19","author":"Garonzik","year":"2019","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"issue":"2","key":"10.1016\/j.dmd.2026.100360_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin","volume":"15","author":"Gouin-Thibault","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.dmd.2026.100360_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10557-023-07443-2","article-title":"Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach","volume":"38","author":"Lenard","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100360_bib12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jcph.352","article-title":"An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function","volume":"54","author":"Moore","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100360_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100360_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100360_bib15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3a4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100360_bib16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.108.023648","article-title":"Relationship between drug\/metabolite exposure and impairment of excretory transport function","volume":"37","author":"Zamek-Gliszczynski","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100360_bib17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1021\/tx300192g","article-title":"Importance of multi-P450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data","volume":"25","author":"Isoherranen","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100360_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.122.001018","article-title":"Hydroxychloroquine is metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and inhibits Cytochrome P450 2D6, while its metabolites also inhibit Cytochrome P450 3A in vitro","volume":"51","author":"Paludetto","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100360_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u201cIn silico\u201d simulations to assess the \u201cin vivo\u201d consequences of \u201cin vitro\u201d metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today Technol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100360_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.dmd.2026.100360_bib22","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100360_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro\u2013in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100360_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106362","article-title":"Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs","volume":"181","author":"Deng","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100360_bib26","series-title":"ICH M12 on drug interaction studies - scientific guideline","year":"2022"},{"issue":"13","key":"10.1016\/j.dmd.2026.100360_bib28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Par\u00e9","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.dmd.2026.100360_bib29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/bcp.12667","article-title":"Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril","volume":"80","author":"Tarkiainen","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100360_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100360_bib31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cpt.1949","article-title":"Effect of high-dose esomeprazole on CYP1A2, CYP2C19, and CYP3A4 activities in humans: evidence for substantial and long-lasting inhibition of CYP2C19","volume":"108","author":"Kaartinen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100360_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.resinv.2020.11.007","article-title":"Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism","volume":"59","author":"Hotta","year":"2021","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.dmd.2026.100360_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.19414","article-title":"Cancer-associated venous thrombosis in adults (second edition): a British Society for Haematology Guideline","volume":"205","author":"Alikhan","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100360_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100360_bib35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.dmd.2026.100360_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.15112","article-title":"BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy","volume":"180","author":"Sibson","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100360_bib37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.dmd.2026.100360_bib38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100360_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bcpt.13088","article-title":"In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug\u2013drug interactions","volume":"123","author":"Filppula","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2026.100360_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106884","article-title":"In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants","volume":"203","author":"Jin","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100360_bib41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/fcp.12769","article-title":"Tyrosine kinase inhibitors and direct oral anticoagulants: in vitro evaluation of drug\u2013drug interaction mediated by P-glycoprotein","volume":"36","author":"Lafaie","year":"2022","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600629X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600629X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:02Z","timestamp":1791996782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600629X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S009095562600629X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100360","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 3-step static mechanistic modeling approach to predicting transporter- and enzyme-mediated interaction signals of direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100360"}}